By Colin Kellaher


Catalyst Pharmaceuticals Inc. on Thursday said the U.S. Food and Drug Administration approved the expanded use of its Firdapse treatment for Lambert-Eaton myasthenic syndrome to include children.

The Coral Gables, Fla., biopharmaceutical company said the drug is now available for patients ages 6 through 17 with the rare condition, in which the immune system attacks the neuromuscular junctions.

In 2018, the FDA approved Firdapse for adults with Lambert-Eaton myasthenic syndrome.


Write to Colin Kellaher at


(END) Dow Jones Newswires

September 29, 2022 11:44 ET (15:44 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.